Mild to Moderate Ulcerative Colitis Clinical Trial
Official title:
BE Study With Clinical Endpoints Comparing Mesalamine Delayed Release Tablets 400 mg to the Reference Listed Drug ASACOL® Delayed Release Tablets 400 mg in Patients With Mild to Moderately Active Ulcerative Colitis
The objectives of this bioequivalence study in patients with ulcerative colitis (UC) were:
- To establish the therapeutic equivalence of mesalamine delayed release tablet (MDRT)
and Asacol Delayed Release Tablets 2.4 g per day (800 mg three times daily) and
- To evaluate the safety of MDRT 2.4 g per day (800 mg three times daily) compared to
placebo.
This was a multi-center, randomized, parallel-groups comparison of two mesalamine products for treatment of ulcerative colitis. Patients were randomly assigned in an optimized 2:2:1 ratio to MDRT 2.4 g/day, Asacol 2.4 g/day, or placebo. The study was partially blinded due to the difficulties associated with creating placebo that matched both MDRT and Asacol; the placebo matched the MDRT formulation. Placebo groups served as control in the parallel group comparison between MDRT and Asacol. Patients were treated for 6 weeks after randomization and followed through Day 56, which was considered of sufficient length to accommodate any safety issues and to assess efficacy based upon prior clinical trials of mesalamine in patients with mild to moderate active UC as described in the introduction ;
Allocation: Randomized, Intervention Model: Parallel Assignment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01201122 -
Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis
|
Phase 4 | |
Completed |
NCT01033305 -
Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyColâ„¢)
|
Phase 2 | |
Recruiting |
NCT05770609 -
A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT01039597 -
Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis
|
Phase 1/Phase 2 |